Pr BIBEAU Frédéric

Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.

Tougeron D, Bibeau F, Chibaudel B, Kim S, Nguyen T, Phelip JM, Mille D, Bouattour M, Tavan D, Rinaldi Y, Lecomte T, Perrier H, Spaeth D, Caroli Bosc FX, Metges JP, Ferec M, Hautefeuille V, Deslandres-Cruchant M, Danion J, Hammel P, Lewin M, Tasu JP, Angelergues A, DiFiore F, Evrard S, Mansar R, Caillou H, Geffriaud-Ricouard C, Adam R

Eur J Cancer. 2024 10 22;213:115082

Education and Training in Peritoneal Surface Oncology.

González-Moreno S, Deraco M, Kusamura S, Bijelic L, Lambert LA, Dromain C, Bibeau F, Liauw W, Reis A, Galan A, Sugarbaker PH

J Surg Oncol. 2024 09 24;:

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.

Westphalen CB, Martins-Branco D, Beal JR, Cardone C, Coleman N, Schram AM, Halabi S, Michiels S, Yap C, André F, Bibeau F, Curigliano G, Garralda E, Kummar S, Kurzrock R, Limaye S, Loges S, Marabelle A, Marchió C, Mateo J, Rodon J, Spanic T, Pentheroudakis G, Subbiah V

Ann Oncol. 2024 08 24;:

Paving the way to a new tumor regression grade in digestive oncology.

Bibeau F, Molimard C

Dig Liver Dis. 2024 07 20;:

Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer.

D'Angelo F, Monnien F, Overs A, Pem I, Dor F, Abad M, Felix S, Selmani Z, Lakkis Z, Borg C, Doussot A, Bibeau F, Molimard C

Diagn Pathol. 2024 06 22;19(1):88

Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts.

Lecuelle J, Truntzer C, Basile D, Laghi L, Greco L, Ilie A, Rageot D, Emile JF, Bibeau F, Taïeb J, Derangere V, Lepage C, Ghiringhelli F

EBioMedicine. 2024 06 15;105:105207

[RENAPE network: Towards more equitable access to care and expertise for patients with rare peritoneal cancers].

Villeneuve L, Odin C, Bonnefoy I, Pichon P, Valmary-Degano S, Bibeau F, ,

Ann Pathol. 2024 06 4;:

WhARIO: whole-slide-image-based survival analysis for patients treated with immunotherapy.

Tourniaire P, Ilie M, Mazières J, Vigier A, Ghiringhelli F, Piton N, Sabourin JC, Bibeau F, Hofman P, Ayache N, Delingette H

J Med Imaging (Bellingham). 2024 05;11(3):037502

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C

Lancet Oncol. 2024 04;25(4):518-528

Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR).

Lecomte T, Tougeron D, Chautard R, Bressand D, Bibeau F, Blanc B, Cohen R, Jacques J, Lagasse JP, Laurent-Puig P, Lepage C, Lucidarme O, Martin-Babau J, Panis Y, Portales F, Taieb J, Aparicio T, Bouché O, , , , , , , , , , , ,

Dig Liver Dis. 2024 02 20;:

Prevalence and significance of HPV DNA detection below the clinical threshold of the commercial kit Alinity m HR-HPV assay (Abbott).

Node J, Dor F, Puget L, Ramanah R, Cot S, Bibeau F, Di Domizio N, Prétet JL, Lepiller Q

J Med Virol. 2024 02;96(2):e29465

CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.

Schoumacher C, Derangère V, Gaudillière-Le Dain G, Huppe T, Rageot D, Ilie A, Vienot A, Borg C, Monnien F, Bibeau F, Truntzer C, Ghiringhelli F,

Oncoimmunology. 2023 12 21;13(1):2294563

Evaluation of immune infiltrate according to the HER2 status in colorectal cancer.

Molimard C, Dor F, Overs A, Monnien F, Gessain G, Kedochim L, D'Angelo F, Abad M, Heberle M, Derangère V, Ghiringhelli F, Vuitton L, Valmary-Degano S, Borg C, Lakkis Z, Bibeau F

Dig Liver Dis. 2023 10 14;:

Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells.

El Baba R, Haidar Ahmad S, Monnien F, Mansar R, Bibeau F, Herbein G

Oncogene. 2023 08 26;:

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.

Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, Laugé C, Catteau A, Boquet I, Majdi A, Morgand E, Oulkhouir Y, Brandone N, Adam J, Sbarrato T, Kassambara A, Fieschi J, Garcia S, Lepage AL, Tomasini P, Galon J

EBioMedicine. 2023 05 25;92:104633

EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes.

El Baba R, Pasquereau S, Haidar Ahmad S, Monnien F, Abad M, Bibeau F, Herbein G

Oncogene. 2023 05 5;:

CD8 CD226 T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery.

Viot J, Abdeljaoued S, Vienot A, Seffar E, Spehner L, Bouard A, Asgarov K, Pallandre JR, Renaude E, Klajer E, Molimard C, Monnien F, Bibeau F, Turco C, Heyd B, Peixoto P, Hervouet E, Loyon R, Doussot A, Borg C, Kroemer M

Cell Mol Immunol. 2023 01 30;:

SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features.

Vienot A, Monnien F, Truntzer C, Mougey V, Bouard A, Pallandre JR, Molimard C, Loyon R, Asgarov K, Averous G, Ghiringhelli F, Bibeau F, Peixoto P, Borg C

Mol Oncol. 2023 01 1;:

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer.

Grancher A, Beaussire L, Manfredi S, Le Malicot K, Dutherage M, Verdier V, Mulot C, Bouché O, Phelip JM, Levaché CB, Deguiral P, Coutant S, Sefrioui D, Emile JF, Laurent-Puig P, Bibeau F, Michel P, Sarafan-Vasseur N, Lepage C, Di Fiore F

Front Oncol. 2022 11 10;12:973167

The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases.

Khellaf L, Quénet F, Jarlier M, Gil H, Pissas MH, Carrère S, Samalin E, Mazard T, Ychou M, Sgarbura O, Bibeau F

Surgery. 2022 09 8;:

Peritoneal metastases of unknown primary with hepatoid features.

Khellaf L, Nougaret S, Carrère S, Bibeau F

Pleura Peritoneum. 2022 09;7(3):157-158

Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.

Coutzac C, Bibeau F, Ben Abdelghani M, Aparicio T, Cohen R, Coquan E, Dubreuil O, Evesque L, Ghiringhelli F, Kim S, Lesourd S, Neuzillet C, Phelip JM, Piessen G, Rochigneux P, Samalin E, Soularue E, Touchefeu Y, Tougeron D, Zaanan A, de la Fouchardière C

Dig Liver Dis. 2022 07 27;:

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

Derangère V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem BM, Ilie A, Bouché O, Phelip JM, Baconnier M, Pezet D, Sebbagh V, Terrebonne E, Bouard G, Jooste V, Bouvier AM, Molimard C, Monnien F, Gonzalez D, Le Malicot K, Rageot D, Truntzer C, Bibeau F, Ghiringhelli F,

Eur J Cancer. 2022 07 1;172:221-230

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.

Boisteau E, Lespagnol A, De Tayrac M, Corre S, Perrot A, Rioux-Leclercq N, Martin-Lannerée S, Artru P, Chalabreysse P, Poureau PG, Doucet L, Coupez D, Bennouna J, Bossard C, Coriat R, Beuvon F, Bauguion L, Leclair F, Chautard R, Lecomte T, Guyetant S, Desgrippes R, Grasset D, Lhostis H, Bouhier-Leporrier K, Bibeau F, Edeline J, Galibert MD, Lièvre A

Clin Res Hepatol Gastroenterol. 2022 Feb 18;:101888

Role of immunohistochemistry for interobserver agreement of Peritoneal Regression Grading Score in peritoneal metastasis.

Detlefsen S, Windedal T, Bibeau F, Bruhn LV, Carr N, Graversen M, Markowski K, Mortensen MB, Neureiter D, Sempoux C, Solass W, Thinesen MT, Fristrup C

Hum Pathol. 2021 Dec 24;:

Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images.

Le Page AL, Ballot E, Truntzer C, Derangère V, Ilie A, Rageot D, Bibeau F, Ghiringhelli F

Sci Rep. 2021 Dec 13;11(1):23912

Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

Delhorme JB, Villeneuve L, Bouché O, Averous G, Dohan A, Gornet JM, You B, Bibeau F, Dartigues P, Eveno C, Fontaine J, Kepenekian V, Pocard M, Rousset P, Quenet F, Mariani P, Glehen O, Goéré D

Dig Liver Dis. 2021 Nov 20;:

Contribution of the Idylla System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of Mutations.

Petiteau C, Robinet-Zimmermann G, Riot A, Dorbeau M, Richard N, Blanc-Fournier C, Bibeau F, Deshayes S, Bergot E, Gervais R, Levallet G

Curr Oncol. 2021 Nov 3;28(6):4432-4445

[Tumour deposition (TD), a probably underestimated poor prognostic criterion, to be taken into account in the therapeutic management of patients with stage III colon cancer].

Delattre JF, Cohen R, Emile JF, Bibeau F, Broudin C, Taieb J, André T, Svrcek M

Ann Pathol. 2021 Nov;41(6):535-543

Is cancer biology different in older patients?

Van Herck Y, Feyaerts A, Alibhai S, Papamichael D, Decoster L, Lambrechts Y, Pinchuk M, Bechter O, Herrera-Caceres J, Bibeau F, Desmedt C, Hatse S, Wildiers H

Lancet Healthy Longev. 2021 10;2(10):e663-e677

Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.

Benzerdjeb N, Dartigues P, Kepenekian V, Valmary-Degano S, Mery E, Avérous G, Chevallier A, Laverriere MH, Villa I, Harou O, Sallé FG, Villeneuve L, Glehen O, Isaac S, Hommell-Fontaine J, Bibeau F,

Virchows Arch. 2021 Oct;479(4):765-772

A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors.

Palassin P, Lapierre M, Pyrdziak S, Wagner A, Stehle R, Corsini C, Duffour J, Bonnet S, Boulahtouf A, Rodriguez C, Ho-Pun-Cheung A, Lopez-Crapez E, Boissière-Michot F, Bibeau F, Thezenas S, Elarouci N, Selves J, Hoffmann JS, Roepman P, Mazard T, Buhard O, Duval A, Jalaguier S, Cavaillès V, Castet-Nicolas A

Cancers (Basel). 2021 Sep 3;13(17):

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryška A, Wolf J, Öhrling K, Burdon P, Malapelle U, Büttner R

Lung Cancer. 2021 04;154:161-175

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

Galland L, Le Page AL, Lecuelle J, Bibeau F, Oulkhouir Y, Derangère V, Truntzer C, Ghiringhelli F

Oncoimmunology. 2021 ;10(1):1957603

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D

Dig Liver Dis. 2020 Dec 21;:

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future.

Hofman P, Ilié M, Chamorey E, Brest P, Schiappa R, Nakache V, Antoine M, Barberis M, Begueret H, Bibeau F, Bonnetaud C, Boström P, Brousset P, Bubendorf L, Carvalho L, Cathomas G, Cazes A, Chalabreysse L, Chenard MP, Copin MC, Côté JF, Damotte D, de Leval L, Delongova P, Thomas de Montpreville V, de Muret A, Dema A, Dietmaier W, Evert M, Fabre A, Forest F, Foulet A, Garcia S, Garcia-Martos M, Gibault L, Gorkiewicz G, Jonigk D, Gosney J, Hofman A, Kern I, Kerr K, Kossai M, Kriegsmann M, Lassalle S, Long-Mira E, Lupo A, Mamilos A, Matěj R, Meilleroux J, Ortiz-Villalón C, Panico L, Panizo A, Papotti M, Pauwels P, Pelosi G, Penault-Llorca F, Pop O, Poté N, Cajal SRY, Sabourin JC, Salmon I, Sajin M, Savic-Prince S, Schildhaus HU, Schirmacher P, Serre I, Shaw E, Sizaret D, Stenzinger A, Stojsic J, Thunnissen E, Timens W, Troncone G, Werlein C, Wolff H, Berthet JP, Benzaquen J, Marquette CH, Hofman V, Calabrese F

ESMO Open. 2020 Dec 2;6(1):100024

Immune scores in colorectal cancer: Where are we?

Malka D, Lièvre A, André T, Taïeb J, Ducreux M, Bibeau F

Eur J Cancer. 2020 11;140:105-118

A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy.

El Sissy C, Kirilovsky A, Van den Eynde M, Muşină AM, Anitei MG, Romero A, Marliot F, Junca A, Doyen J, Mlecnik B, Haicheur N, Fredriksen T, Lagorce C, Jouret-Mourin A, Leonard D, Bibeau F, Iseas S, Roca EL, Cabanne AM, Vaccaro CA, Santino JP, Huertas E, Tougeron D, Carvalho C, Figueiredo N, Perez RO, Habr-Gama A, Scripcariu V, Gerard JP, Galon J, Zeitoun G, Pagès F

Clin Cancer Res. 2020 10 1;26(19):5198-5207

Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).

Samalin E, Fouchardière C, Thézenas S, Boige V, Senellart H, Guimbaud R, Taïeb J, François E, Galais MP, Lièvre A, Seitz JF, Metges JP, Bouché O, Boissière-Michot F, Lopez-Crapez E, Bibeau F, Ho-Pun-Cheung A, Ychou M, Adenis A, Di Fiore F, Mazard T

Clin Colorectal Cancer. 2020 May 15;:

Bibeau F, Léger A, Bazille C, Selves J

Ann Pathol. 2020 Apr;40(2):105-113

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR).

Delattre JF, Cohen R, Henriques J, Falcoz A, Emile JF, Fratte S, Chibaudel B, Dauba J, Dupuis O, Bécouarn Y, Bibeau F, Taieb J, Louvet C, Vernerey D, André T, Svrcek M

J. Clin. Oncol.. 2020 Mar 13;:JCO1901960

Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept.

Sgarbura O, Al Hosni M, Petruzziello A, Figueroa R, Khellaf L, Pissas MH, Carrère S, Nougaret S, Bibeau F, Quénet F

Int J Hyperthermia. 2020 ;37(1):585-591

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS

Ann Oncol. 2019 09 1;30(9):1417-1427

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.

Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A

Ann Oncol. 2019 08 1;30(8):1232-1243

Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis.

Solass W, Sempoux C, Carr NJ, Bibeau F, Neureiter D, Jäger T, Di Caterino T, Brunel C, Klieser E, Fristrup CW, Mortensen MB, Detlefsen S

Histopathology. 2019 Jun;74(7):1014-1024

National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016.

Boutanos C, Capdepont M, Svrcek M, Thélu F, Guedj N, Poizat F, Bibeau F, Turlin B, Rousseau A, Bardier A, Selves J, Desrousseaux M, Le Pessot F, Bonhomme B, Laverrière MH, Julié C, Eyremandi RP, Stanislas S, Bazille C, Daubech A, Lazure T, Bordier MS, Demoures A, Rullier A

Virchows Arch. 2019 May;474(5):561-568

Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients.

Hofman V, Rouquette I, Long-Mira E, Piton N, Chamorey E, Heeke S, Vignaud JM, Yguel C, Mazières J, Lepage AL, Bibeau F, Begueret H, Lassalle S, Lalvée S, Zahaf K, Benzaquen J, Poudenx M, Marquette CH, Sabourin JC, Ilié M, Hofman P

J Thorac Oncol. 2019 Apr 15;:

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.

Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R, Bertheau P, Renaud F, Bibeau F, Fléjou JF, André T, Svrcek M, Duval A

JAMA Oncol. 2019 Apr 1;5(4):551-555

Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival.

Quénet F, Pissas MH, Gil H, Roca L, Carrère S, Sgarbura O, Rouanet P, de Forges H, Khellaf L, Deshayes E, Ychou M, Bibeau F

Surgery. 2019 04;165(4):703-711

[Augmented pathology, future or present ?]

Badoual C, Bibeau F

Ann Pathol. 2019 Apr;39(2):71-72

[Tumor banks and complex data management: Current and future challenges].

Hofman P, Dagher G, Laurent-Puig P, Marquette CH, Barlesi F, Bibeau F, Clément B

Ann Pathol. 2019 Apr;39(2):137-143

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.

Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron D,

Br. J. Cancer. 2019 Mar 22;:

Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.

Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A, Naoures Mear CL, Bibeau F, Marguet F, Guisier F, Salaün M, Thiberville L, Jardin F, Sabourin JC

Lab Invest. 2018 03;98(3):371-379

The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei.

Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, Gui X, Isaac S, Milione M, Misdraji J, Pai RK, Rodriguez-Justo M, Sobin LH, van Velthuysen MF, Yantiss RK

Histopathology. 2017 Dec;71(6):847-858

[FREGAT: French clinico-biological database dedicated to esogastric cancers].

Renaud F, Bibeau F, Leteurtre E, Delaeter C, Dib M, Harter V, Adenis A, Piessen G, Mariette C,

Ann Pathol. 2017 Dec;37(6):457-466

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

Cohen R, Buhard O, Cervera P, Hain E, Dumont S, Bardier A, Bachet JB, Gornet JM, Lopez-Trabada D, Dumont S, Kaci R, Bertheau P, Renaud F, Bibeau F, Parc Y, Vernerey D, Duval A, Svrcek M, André T

Eur. J. Cancer. 2017 11;86:266-274

Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.

Prieur A, Cappellini M, Habif G, Lefranc MP, Mazard T, Morency E, Pascussi JM, Flacelière M, Cahuzac N, Vire B, Dubuc B, Durochat A, Liaud P, Ollier J, Pfeiffer C, Poupeau S, Saywell V, Planque C, Assenat E, Bibeau F, Bourgaux JF, Pujol P, Sézeur A, Ychou M, Joubert D

Clin Cancer Res. 2017 Sep 1;23(17):5267-5280

Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function.

Guiu B, Quenet F, Escal L, Bibeau F, Piron L, Rouanet P, Fabre JM, Jacquet E, Denys A, Kotzki PO, Verzilli D, Deshayes E

Eur Radiol. 2017 Aug;27(8):3343-3352

Antibody targeting of claudin-1 as a potential colorectal cancer therapy.

Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M

J Exp Clin Cancer Res. 2017 06 28;36(1):89

Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.

Valmary-Degano S, Colpart P, Villeneuve L, Monnien F, M'Hamdi L, Lang Averous G, Capovilla M, Bibeau F, Laverriere MH, Verriele-Beurrier V, Ben Rejeb H, Dartigues P, Hommell-Fontaine J, Gilly FN, Isaac S, Mery E,

Eur J Surg Oncol. 2017 May;:

Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.

Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P

Eur J Cancer. 2017 05;76:68-75

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Gérard JP, André T, Bibeau F, Conroy T, Legoux JL, Portier G, Bosset JF, Cadiot G, Bouché O, Bedenne L,

Dig Liver Dis. 2017 Apr;49(4):359-367

The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry.

Villeneuve L, Passot G, Glehen O, Isaac S, Bibeau F, Rousset P, Gilly FN,

Orphanet J Rare Dis. 2017 02 17;12(1):37

[A special issue dedicated to immuno-oncology].

Bibeau F, Badoual C

Ann Pathol. 2017 Feb;37(1):1-2

[Immune response and digestive cancers: Prognostic and therapeutic implications].

Bibeau F, Bazille C, Svrcek M, Pierson R, Lagorce-Pagès C, Cohen R, André T

Ann Pathol. 2017 Feb;37(1):111-116

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V

Clin. Chem.. 2016 Aug;62(8):1129-39

Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.

Boissière-Michot F, Frugier H, Ho-Pun-Cheung A, Lopez-Crapez E, Duffour J, Bibeau F

Virchows Arch. 2016 Aug;469(2):135-44

Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses.

Nougaret S, Vargas HA, Lakhman Y, Sudre R, Do RK, Bibeau F, Azria D, Assenat E, Molinari N, Pierredon MA, Rouanet P, Guiu B

Radiology. 2016 08;280(2):446-54

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G

Nat Commun. 2016 Jul;7:12222

Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.

El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR

Clin Cancer Res. 2016 06 15;22(12):3067-77

Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS).

Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F

Pleura Peritoneum. 2016 Jun 1;1(2):99-107

Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options.

Duffour J, Combes A, Crapez E, Boissière-Michot F, Bibeau F, Senesse P, Ychou M, Courraud J, de Forges H, Roca L

J Genet Couns. 2016 06;25(3):432-42

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.

Jacot W, Mollevi C, Fina F, Lopez-Crapez E, Martin PM, Colombo PE, Bibeau F, Romieu G, Lamy PJ

BMC Cancer. 2015 Dec 18;15:986

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M,

Ann Oncol. 2015 Dec;26(12):2442-9

Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.

Colombo PE, du Manoir S, Orsett B, Bras-Gonçalves R, Lambros MB, MacKay A, Nguyen TT, Boissière F, Pourquier D, Bibeau F, Reis-Filho JS, Theillet C

Oncotarget. 2015 Sep 29;6(29):28327-40

[Peritoneal tumor pathology - case no. 6: major histologic colloid response of colorectal peritoneal carcinomatosis after induction treatment].

Bibeau F

Ann Pathol. 2015 Aug;35(4):347-50

[Peritoneal tumor pathology - case no. 8: desmoplastic small round cell tumor].

Bibeau F

Ann Pathol. 2015 Aug;35(4):357-61

Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.

Lamy PJ, Castan F, Lozano N, Montélion C, Audran P, Bibeau F, Roques S, Montels F, Laberenne AC

J Mol Diagn. 2015 Jul;17(4):366-73

Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey.

Ferron G, Simon L, Guyon F, Glehen O, Goere D, Elias D, Pocard M, Gladieff L, Bereder JM, Brigand C, Classe JM, Guilloit JM, Quenet F, Abboud K, Arvieux C, Bibeau F, De Chaisemartin C, Delroeux D, Durand-Fontanier S, Goasguen N, Gouthi L, Heyd B, Kianmanesh R, Leblanc E, Loi V, Lorimier G, Marchal F, Mariani P, Mariette C, Meeus P, Msika S, Ortega-Deballon P, Paineau J, Pezet D, Piessen G, Pirro N, Pomel C, Porcheron J, Pourcher G, Rat P, Regimbeau JM, Sabbagh C, Thibaudeau E, Torrent JJ, Tougeron D, Tuech JJ, Zinzindohoue F, Lundberg P, Herin F, Villeneuve L

Eur J Surg Oncol. 2015 Jul 29. pii: S0748-7983(15)00555-7

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.

Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A

Oncotarget. 2015 May 20;6(14):12796-808

The Lauren classification highlights the role of epithelial-to-mesenchymal transition in gastric carcinogenesis: an immunohistochemistry study of the STAT3 and adhesion molecules expression.

Susman S, Barnoud R, Bibeau F, Borrini F, Pocard M, Tomuleasa C, Sabourin JC

J Gastrointestin Liver Dis. 2015 03;24(1):77-83

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Manceau G, Imbeaud S, Thiebaut R, Liebaert F, Fontaine K, Rousseau F, Genin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouche O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamaki R, Sarhadi V, Knuutila S, Boige V, Andre T, Laurent-Puig P

Clin Cancer Res. 2014 Jun 15;20(12):3338-47

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

Samalin E, Bouche O, Thezenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissiere F, Laurent-Puig P, Ychou M, Mazard T

Br J Cancer. 2014 Mar 4;110(5):1148-54

[Peritoneal pseudomyxoma: an overview emphasizing pathological assessment and therapeutic strategies].

Dartigues P, Isaac S, Villeneuve L, Glehen O, Capovilla M, Chevallier A, Croce S, Kaci R, Lang-Averous G, Laverriere MH, Leroux-Broussier A, Mery É, Poizat F, Valmary-Degano S, Verriele-Beurrier V, Gilly FN, Bibeau F

Ann Pathol. 2014 Feb;34(1):14-25

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2.

Rullier A, Gourgou-Bourgade S, Jarlier M, Bibeau F, Chassagne-Clement C, Hennequin C, Tisseau L, Leroux A, Ettore F, Peoc'h M, Diebold MA, Robin YM, Kleinclaus I, Mineur L, Petitjean C, Mosnier JF, Soubeyran I, Padilla N, Lemaistre AI, Berille J, Denis B, Conroy T, Gerard JP

Eur J Cancer. 2013 Jan;49(1):82-9

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretiere JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bieche I, Penault-Llorca F

BMC Cancer. 2013 Jul 22;13:351

A refined molecular taxonomy of breast cancer.

Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C

Oncogene. 2012 Mar 1;31(9):1196-206

[HER2 and gastric cancer. Recommendations for clinical practice in 2011].

Penault-Llorca F, Chenard MP, Bouche O, Emile JF, Bibeau F, Metges JP, Andre T, Monges G

Ann Pathol. 2011 Apr;31(2):78-87

[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].

Penault-Llorca F, Vincent-Salomon A, Bellocq JP, Matthieu MC, Grogan GM, Treilleux I, Ettore F, Laberge-Le Couteulx S, Sigal B, Couturier J, Lacroix-Triki M, Antoine M, Balaton A, Baranzelli MC, Becette V, Blanc-Fournier C, Bibeau F, Brabencova E, Croce S, Fridman V, Genin P, Ghnassia JP, Jacquemier J, Poulet B, Roger P, Sagan C, Tas P, Trassard M, Verriele V, Arnould L

Ann Pathol. 2010 Oct;30(5):357-73

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

Perkins G, Lievre A, Ramacci C, Meatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouche O, Penault-Llorca F, Merlin JL, Laurent-Puig P

Int J Cancer. 2010 Sep 1;127(6):1321-31.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche O, Reid J, Stone S, Penault-Llorca F

J Clin Oncol. 2009 Dec 10;27(35):5924-30

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.

Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M

Nat Med. 2009 Jan;15(1):68-74

Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.

MacGrogan G, Arnould L, de Mascarel I, Vincent-Salomon A, Penault-Llorca F, Lacroix-Triki M, Bibeau F, Baranzelli MC, Fridman V, Antoine M, Becette V, Brouste V, Jacquemier J, Mathoulin-Pelissier S

Histopathology. 2008 May;52(6):689-97

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P

J Clin Oncol. 2008 Jan 20;26(3):374-9.

Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?

Penault-Llorca F, Cayre A, Arnould L, Bibeau F, Bralet MP, Rochaix P, Savary J, Sabourin JC

Oncol Rep. 2006 Dec;16(6):1173-9.

High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study.

Lacroix-Triki M, Mathoulin-Pelissier S, Ghnassia JP, Macgrogan G, Vincent-Salomon A, Brouste V, Mathieu MC, Roger P, Bibeau F, Jacquemier J, Penault-Llorca F, Arnould L

Eur J Cancer. 2006 Nov;42(17):2946-53

Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray.

Bibeau F, Boissiere-Michot F, Sabourin JC, Gourgou-Bourgade S, Radal M, Penault-Llorca F, Rochaix P, Arnould L, Bralet MP, Azria D, Ychou M

Virchows Arch. 2006 Sep;449(3):281-7

[EGFR expression in colorectal cancer and role in tumorigenesis].

Penault-Llorca F, Bibeau F, Arnould L, Bralet MP, Rochaix P, Sabourin JC

Bull Cancer. 2005 Aug;92(Spec no):S5-11.